4,901 trials
Pancreatic Cancer
Primary: The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant…
Prostate Specific Antigens · Prostate Neoplasms
Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…
Healthy Volunteers
Primary: Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide — 217.2; 237.2; 221.9; 253.0…
Metastatic Gastric Cancer · Metastatic Breast Cancer · Metastatic Colorectal Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 3; 3 Participants
Opioid Dependence
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 2; 3; 3 Participants
Diabetes Type 2 · Dementia
Primary: Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)--Whole Brain — 12.28; 11.75 micromoles/min/100g tissue
Recurrent Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide — 35 mg/m^2
Hearing Impairment, Sensorineural
Primary: Change in Hearing Aid Satisfaction After Auditory Training — 1.9; 1.7 units on a scale — p==0.269
Peripheral T-cell Lymphoma NOS · Mycosis Fungoides · Sezary Syndrome
Primary: Maximum Tolerated Dose (MTD) of Interleukin 15 — NA; NA mcg/kg
Breast Neoplasms · Breast Cancer · Adenocarcinomas
Primary: Number of Participants With Cardiac Toxicity — 6; 7; 6; 6 Participants
Polio
Primary: Number of Participants With Serious Adverse Events Over the Course of the Study — 0; 0; 0 Participants
HIV-1-infection
Primary: Number of Participants With Treatment-Emerging Adverse Events — 1; 1; 4; 3 Participants
Substance Use Disorders
Primary: Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) From Baseline to Post-treatment at 8 Weeks — -9.3 score on a scale
Mesothelioma
Primary: Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel — 140; 100 mcg
Parkinson's Disease
Primary: Feasibiilty of Ketogenic Diet - Retention (Co-primary Endpoint) — 15 Participants